Teva Pharmaceutical Industries (NYSE:TEVA) Announces Quarterly Earnings Results

28 Jan 2026, 09:56 by Scott Moore · The Cerbat Gem

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.31, FiscalAI reports. Teva Pharmaceutical Industries had a return on equity of 46.13% and a net margin of 4.24%.Teva Pharmaceutical Industries’s revenue was up 11.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.71 earnings per share. Teva Pharmaceutical Industries updated its FY 2026 guidance to 2.570-2.770 EPS.

Here are the key takeaways from Teva Pharmaceutical Industries’ conference call:

Management reported year-over-year growth in revenue and profitability, noting EBITDA up ~12%, EPS up ~19% and free cash flow improvement, which management says supports their pivot to an innovative biopharma model.
The commercial portfolio is driving momentum—AUSTEDO, UZEDY and AJOVY delivered strong sales with AUSTEDO guidance of $2.4B–$2.55B and rapid uptake of AUSTEDO XR and UZEDY long‑acting injectable volumes cited as growth drivers.
Several near‑term R&D catalysts are expected in 2026, including duvakitug maintenance data (H1), olanzapine LAI EU submission/anticipated approval, Anti‑IL‑15 vitiligo and celiac readouts, and completion of the DARI phase‑3 asthma study.
Financial restructuring and efficiency progress — net debt reduced to about $13B (~2.5x EBITDA), $70M of transformation savings realized toward a $700M target by 2027, and management expects improving margins and deleveraging toward investment‑grade metrics.
Management flagged near‑term headwinds and one‑offs: an expected ~ $1.1B generic Revlimid revenue decline in 2026, Q1 softness from Revlimid and AUSTEDO destocking/gross‑to‑net effects, and a Q4 impairment charge (~$773M) that weighed on GAAP results.

Teva Pharmaceutical Industries Stock Down 2.5%

Shares of NYSE:TEVA opened at $31.72 on Wednesday. The company has a 50 day moving average price of $29.94 and a two-hundred day moving average price of $22.89. The company has a market capitalization of $36.38 billion, a PE ratio of 52.36, a PEG ratio of 1.83 and a beta of 0.66. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $33.42. The company has a debt-to-equity ratio of 2.31, a quick ratio of 0.82 and a current ratio of 1.11.

Insider Activity

In other Teva Pharmaceutical Industries news, CAO Amir Weiss sold 12,300 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $30.20, for a total transaction of $371,460.00. Following the transaction, the chief accounting officer directly owned 5,650 shares in the company, valued at approximately $170,630. The trade was a 68.52% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Richard Daniell sold 115,468 shares of the stock in a transaction dated Tuesday, December 9th. The stock was sold at an average price of $28.68, for a total value of $3,311,622.24. Following the completion of the sale, the vice president owned 48,384 shares of the company’s stock, valued at $1,387,653.12. This trade represents a 70.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 622,060 shares of company stock worth $17,076,965 in the last 90 days. Corporate insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. CIBC Private Wealth Group LLC increased its position in shares of Teva Pharmaceutical Industries by 15.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock worth $81,000 after purchasing an additional 540 shares during the last quarter. CIBC Bancorp USA Inc. bought a new position in shares of Teva Pharmaceutical Industries in the third quarter valued at $234,000. Danske Bank A S acquired a new position in Teva Pharmaceutical Industries during the third quarter worth $5,012,000. Advisory Services Network LLC raised its position in Teva Pharmaceutical Industries by 11.1% during the third quarter. Advisory Services Network LLC now owns 53,055 shares of the company’s stock worth $1,072,000 after acquiring an additional 5,318 shares in the last quarter. Finally, NewEdge Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 5.2% in the third quarter. NewEdge Advisors LLC now owns 44,150 shares of the company’s stock valued at $892,000 after acquiring an additional 2,180 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on TEVA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, January 21st. JPMorgan Chase & Co. upped their price target on Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Scotiabank began coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, December 5th. They set a “sector outperform” rating and a $35.00 target price on the stock. Barclays assumed coverage on Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $35.00 price target on the stock. Finally, Jefferies Financial Group increased their price target on Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Three equities research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Teva Pharmaceutical Industries presently has an average rating of “Buy” and a consensus target price of $33.67.

Get Our Latest Stock Report on Teva Pharmaceutical Industries

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.